Baby & Kids Skincare Private Label: The Compliance Gaps US and EU Founders Miss (2026 MoCRA + CPNP Guide)

There is a dangerous assumption behind most baby skincare launches: that "gentle" is a formulation decision. In the US it is a documentation decision. In the EU it is a legal one.

Why baby skincare is the hardest easy category

Kids' skincare looks like a soft entry point. Small SKU count, high repeat purchase, parents who do not price-shop. That is all true. What founders underestimate is that the regulatory exposure per SKU is higher than anything else on a beginner's roadmap — and that exposure sits with the brand, not the factory.

The commercial case is real

The economics are friendly. The paperwork is not. That asymmetry is the whole article.

Infant versus child is not a marketing segment

Under EU rules the split at three years old is a hard regulatory line, not a positioning choice. Under US rules there is no line at all — which sounds easier and is actually worse, because nothing external tells you when you have gone too far.

The regulatory core: two very different systems

This is the part that does not translate between markets, so treat US and EU as separate projects even if the bulk tank is identical.

United States — MoCRA, and the absence of a kids' category

The Modernization of Cosmetics Regulation Act does not create a children's cosmetic classification. Your baby lotion is regulated as a cosmetic, full stop. What MoCRA does require:

• Facility registration — the manufacturing site must be registered with FDA. If your contract manufacturer is in China, that facility still needs to be registered. Ask for the registration number, do not accept "we are compliant."
• Product listing — each product, listed, with its ingredient statement.
• Safety substantiation — you must hold adequate evidence that the product is safe. There is no government pre-approval to hide behind; the file is your defence.
• Adverse event reporting — serious events reported within 15 business days, records retained.
• Responsible Person — named on the label. For an importing DTC brand, that is usually you, not the factory.

The practical consequence: because no regulator vets your baby formula before launch, the only thing standing between you and an FTC or class-action problem is the quality of your substantiation dossier. Brands that treat this as a formality are the ones that get hurt.

Separately, MoCRA directed FDA toward standardised talc testing — relevant if you are considering a baby powder. The simplest risk decision is to formulate talc-free with a starch base and say so.

European Union / UK — CPNP, and a real children's regime

The EU does the opposite. Regulation 1223/2009 requires notification through CPNP before placing on the market, a designated Responsible Person established in the EU, and a Product Information File. The children-specific parts that catch people out:

• The safety assessment must specifically consider children under three. A generic assessment copied from an adult line will be rejected by any competent assessor.
• Propylparaben and butylparaben are prohibited in leave-on products intended for the nappy area for children under three. If your factory's default preservative blend contains them, your diaper balm is non-compliant before you print a label.
• Methylisothiazolinone (MI) is banned in leave-on cosmetics generally — including baby lotions.
• Full ingredient and allergen labelling applies; there is no "proprietary blend" escape hatch.

The UK mirrors this through UKCA with a UK-based Responsible Person and its own submission portal. Same dossier, two filings, two RPs. Budget for both.

Evidence note: "hypoallergenic" is not a defined regulatory term in either market. It signals intent, not proof. If you use it, you need supporting data — and your assessor will ask for it.

Formulation: what to remove, what is actually supported

The Chinese-market version of this guide leans on a national children's-cosmetic mark. There is no equivalent badge in the US or EU, so your formulation itself has to carry the credibility.

The exclusion list

What is genuinely supported

Colloidal oatmeal is the strongest evidence position available to you — it is an FDA-recognised OTC skin protectant monograph ingredient, which gives you a defensible functional claim rather than a marketing adjective. Ceramides and glycerin are well-supported for barrier support. Beyond that, restraint is the strategy: a nine-ingredient lotion that a dermatologist can read in ten seconds outperforms a twenty-eight-ingredient "clinical" formula in this category.

The claim trap

"Pediatrician tested" means a paediatrician was involved. It does not mean efficacy was demonstrated, and the FTC expects you to be able to explain the difference. "Tear-free" is a testing claim requiring ocular data. "Clinically proven" without a study is the single fastest route to a warning letter.

Vetting the manufacturer: what a baby line actually requires

Any factory will say yes to a baby line. Very few are set up for one.

Non-negotiables

The acute oral toxicity test matters more here than in adult skincare for an obvious reason: infants put lotioned hands in their mouths. If a factory has never commissioned that test, they have never actually made a compliant infant product.

Five failure patterns

1. Adult formula, new label. No dedicated line, no reformulation — just a different carton. Verify the line physically or by live video, and check the licence scope.
2. Borrowed credentials. The registered facility is not the facility making your goods. Cross-check the production address against the registration.
3. Hidden actives. "Botanical complex" concealing a fragrance allergen or a restricted preservative. Demand the complete INCI with percentages, in writing, in the contract.
4. Token testing. Two of the four toxicology endpoints, from a lab nobody has heard of. Specify the endpoints and accepted labs in the agreement.
5. Preservative default. The factory's house preservative system is optimised for adult product and may not clear the EU nappy-area restrictions. Ask specifically.

A useful test question: "Show me a baby product you made in the last twelve months that is currently notified in CPNP." The answer separates real capability from sales enthusiasm.

Launching without tripping over your own marketing

Parents in the US and EU buy on transparency signals, not on active ingredients. That works in your favour: the cheapest formula to defend is also the most persuasive one.

"Unscented" can mean a masking fragrance was used. "Fragrance-free" means none was added. Parents who read ingredient lists know the difference, and those are exactly the parents who write reviews.

A realistic first run

Two SKUs — a wash and a lotion — at low MOQ, fragrance-free, ISO 8 production, full toxicology package, one shared safety assessment structure adapted per region. Sampling in roughly two to three weeks, production in four to six, plus notification lead time on the EU side. Do not launch a diaper balm first; the nappy-area preservative restrictions make it the hardest SKU in the range, not the easiest.

---

🔗 Need a manufacturer that can actually document an infant-grade line — registration, cleanroom class, dedicated production and the full toxicology set? Send us your target market and SKU list → https://www.quickoem.com/en/contact